SEARCH:   Advanced

Blood, 15 December 2003, Vol. 102, No. 13, pp. 4270-4276. Prepublished online as a Blood First Edition Paper on August 21, 2003; DOI 10.1182/blood-2003-05-1699. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-05-1699v1 102/13/4270    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kluin-Nelemans, H. C. Articles by Fijnheer, R. Search for Related Content PubMed PubMed Citation Articles by Kluin-Nelemans, H. C. Articles by Fijnheer, R. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cladribine therapy for systemic mastocytosis Hanneke C. Kluin-Nelemans, J. Marja Oldhoff, Jasper J. van Doormaal, Jan W. van 't Wout, Gregor Verhoef, Wim B. J. Gerrits, O. Aart van Dobbenburgh, Suzanne G. Pasmans, and Rob Fijnheer From the Department of Hematology, University Hospital Groningen, the Netherlands; the Department of Allergology, University Hospital Groningen, the Netherlands; the Department of Dermatology, University Medical Center Utrecht, the Netherlands; the Department of Hematology, University Medical Center Utrecht, the Netherlands; the Department of Internal Medicine, Bronovo Hospital, The Hague, the Netherlands; the Department of Hematology, Leyenburg Hospital, The Hague, the Netherlands; the Department of Internal Medicine, Gelre Hospital, Zutphen, the Netherlands; and the Department of Hematology, University Hospital, Leuven, Belgium. Patients with systemic mastocytosis (SM) can suffer from disabling symptoms related to mast cell mediator release or mast cell infiltration, requiring mast cell eradication. In the present absence of any curative therapy, a recent case report describing the efficacy of cladribine showed promising results. In a pilot study, the efficacy of cladribine (0.10-0.13 mg/kg in a 2-hour infusion, days 1-5; repeated at 4-8 weeks until 6 cycles) was studied. Ten patients with SM with severe symptoms were treated. Four patients were classified as having indolent or smoldering mastocytosis, 3 as having aggressive systemic mastocytosis, and 3 as having SM with an accompanying hematologic malignancy. Nine patients received 6 courses, 1 patient stopped because of toxicodermia. All responded concerning signs, symptoms, and mast cell parameters (serum tryptase and urinary histamine metabolite excretion), although none achieved a complete remission. Prolonged follow-up is required, as response is ongoing in most cases. One patient relapsed within 11 months and showed a second response. Side effects were mainly related to bone marrow suppression. Single-agent cladribine is an effective and relatively safe treatment for severe systemic mastocytosis. The optimal dose and schedule need to be explored. (Blood. 2003;102:4270-4276) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. D. Metcalfe Mast cells and mastocytosis Blood, August 15, 2008; 112(4): 946 - 956. [Abstract] [Full Text] [PDF] C. Sucker, G. Mansmann, S. Steiner, N. Gattermann, A. Schmitt-Graeff, R. Loncar, R. E. Scharf, and M. Stockschlader Fatal Bleeding Due to a Heparin-Like Anticoagulant in a 37-Year-Old Woman Suffering From Systemic Mastocytosis Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 360 - 364. [Abstract] [PDF] S. Verstovsek, A. Tefferi, J. Cortes, S. O'Brien, G. Garcia-Manero, A. Pardanani, C. Akin, S. Faderl, T. Manshouri, D. Thomas, et al. Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis Clin. Cancer Res., June 15, 2008; 14(12): 3906 - 3915. [Abstract] [Full Text] [PDF] A. Tefferi, S. Verstovsek, and A. Pardanani How we diagnose and treat WHO-defined systemic mastocytosis in adults Haematologica, January 1, 2008; 93(1): 6 - 9. [Full Text] [PDF] M.T. Krauth, M. Fodinger, L. Rebuzzi, R. Greul, A. Chott, and P. Valent Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens Haematologica, December 1, 2007; 92(12): e126 - e129. [Full Text] [PDF] K. V. Gleixner, M. Mayerhofer, K. Sonneck, A. Gruze, P. Samorapoompichit, C. Baumgartner, F. Y. Lee, K. J. Aichberger, P. W. Manley, D. Fabbro, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT Haematologica, November 1, 2007; 92(11): 1451 - 1459. [Abstract] [Full Text] [PDF] K. J. Aichberger, M. Mayerhofer, K. V. Gleixner, M.-T. Krauth, A. Gruze, W. F. Pickl, V. Wacheck, E. Selzer, L. Mullauer, H. Agis, et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412 Blood, April 1, 2007; 109(7): 3031 - 3041. [Abstract] [Full Text] [PDF] D. P. Steensma and R. E. Richard Myeloproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 172 - 227. [Full Text] [PDF] M. Gabillot-Carre, Y. Lepelletier, M. Humbert, P. de Sepuvelda, N. B. Hamouda, J. P. Zappulla, R. Liblau, A. Ribadeau-Dumas, F. Machavoine, S. Letard, et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells Blood, August 1, 2006; 108(3): 1065 - 1072. [Abstract] [Full Text] [PDF] K. V. Gleixner, M. Mayerhofer, K. J. Aichberger, S. Derdak, K. Sonneck, A. Bohm, A. Gruze, P. Samorapoompichit, P. W. Manley, D. Fabbro, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects Blood, January 15, 2006; 107(2): 752 - 759. [Abstract] [Full Text] [PDF] J. Gotlib, C. Berube, J. D. Growney, C.-C. Chen, T. I. George, C. Williams, T. Kajiguchi, J. Ruan, S. L. Lilleberg, J. A. Durocher, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation Blood, October 15, 2005; 106(8): 2865 - 2870. [Abstract] [Full Text] [PDF] A. S. Corbin, S. Demehri, I. J. Griswold, Y. Wang, C. A. Metcalf III, R. Sundaramoorthi, W. C. Shakespeare, J. Snodgrass, S. Wardwell, D. Dalgarno, et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit Blood, July 1, 2005; 106(1): 227 - 234. [Abstract] [Full Text] [PDF] A. S. Corbin, I. J. Griswold, P. La Rosee, K. W. H. Yee, M. C. Heinrich, C. L. Reimer, B. J. Druker, and M. W. N. Deininger Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970 Blood, December 1, 2004; 104(12): 3754 - 3757. [Abstract] [Full Text] [PDF] S. O'Brien, A. Tefferi, and P. Valent Chronic Myelogenous Leukemia and Myeloproliferative Disease Hematology, January 1, 2004; 2004(1): 146 - 162. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020